PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of […]
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Lung most cancers is the primary explanation for cancer-related deaths on the earth. Sufferers handled with present chemotherapies for non-small-cell lung cancers (NSCLCs) have a […]
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Cells which might be poor in homologous recombination, resembling people who lack useful breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) […]
Targeted therapy for cancer using PARP inhibitors.
Poly (ADP-ribose) Polymerase (PARP) has a well-established function in DNA restore processes, and small molecule inhibitors of PARP have been developed as chemotherapy sensitisers for […]
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Whereas target-specific medication can be found for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailor-made remedy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary […]